DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumor Cell Line Screening Panel

Biomarkers

Volumn 10, Issue 2-3, 2005, Pages 188-202

  Yarosh, Dan B ^a   Pena A ^a   Brown, D A ^a  

^a AGI Dermatics   (United States)

Author keywords

8 oxo guanine; Cytotoxicity; Human DNA repair genes; Nitric oxide synthetase; Polymorphisms

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; AMSACRINE; ANTINEOPLASTIC AGENT; APHIDICOLIN; BUSULFAN; CAMPTOTHECIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLOROZOTOCIN; CISPLATIN; COLCHICINE; CYCLODISONE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; MELPHALAN; MESYLMESYLIC ACID 2 CHLOROETHYL ESTER; METHOTREXATE; MITOMYCIN C; MITOZOLOMIDE; PACLITAXEL; SEMUSTINE; SPIROMUSTINE; TENIPOSIDE; TETRAPLATIN; THIOTEPA; TIOGUANINE; URAMUSTINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA POLYMORPHISM; DNA REPAIR; EXCISION REPAIR; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; PREDICTION; REGULATORY MECHANISM; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; GUANINE; HUMANS; MUTATION; POLYMORPHISM, GENETIC;

EID: 21444459236     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13547500500138732     Document Type: Article

References (28)

1. Au W, Salama S, Sierra-Torres C. 2003. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Env Hlth Persp 111:1843-1850.
2. Cadet J, Weingeld M. 1993. Detecting DNA damage. Analyt Chem 65:675-682.
3. Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. 2003. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 170:2471-2474.
4. Cho EY, Hildesheim A, Chen CJ, Hsu MM, Chen IH, Mittl BF, Levine BH, Liu MY, Chen JY. 2003. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epid Biom Prev 12:1100-1104.
5. Dherin C, Radicella J, Dizdaroglu M, Boiteux S. 1999. Excision of oxidatively damaged DNA bases by the human α-hOGG1 protein and the polymorphic α-hOGG1 (Ser326Cys) protein which is frequently found in human populations. Nucl Acids Res 27:4001-4007.
6. Frebourg T, Friend SH. 1992. Cancer risks from germ line p53 mutations. J Clin Invest 90:1637-1641.
7. Fukunaga-Takenaka R, Fukunaga K, Tatemichi M, Ohshima H. 2003. Nitric oxide prevents UV-induced phosphorylation of the p53 tumor-suppressor protein at serine 46: a possible role in inhibition of apoptosis. Biochem Biophys Res Comm 308:966-974.
8. Ghilardi G, Biondi M, Cecchini F, DeMonti M, Guagnellini E. 2003. Vascular invasions in human breast cancer are correlated to T→786C polymorphism of NOS3 gene. Nitric Oxide 9:118-122.
9. Ghilardi G, Biondi M, DeMonti M, Bernini M, Turri O, Massaro F, Guagnellini E, Scorza R. 2002. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthetase gene. Clin Chem 48:989-993.
10. Goode E, Ulrich C, Potter J. 2002. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epid Biom Prev 11:1513-1530.
11. Hou SM, Ryk C, Kannio A, Angelini S, Fält S, Nyberg F, Husgafval-Pursiainen K. 2003. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environ Mol Mutagen 41:37-42.
12. Janssen K, Schlink K, Gotte W, Hippler B, Kaina B, Oesch F. 2001. DNA repair activity of 8-oxoguanine DNA glycosylase I (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 486:207-216.
13. Kohno T, Shinmura K, Tosaka M, Tani M, Kim S, Sugimura H, Nohmi T, Kasai H, Yokota J. 1988. Genetic polymorphisms and alternative splicing of the hOOG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 16:3219-3225.
14. Kondo S, Satoh Y, Kuroki T. 1989. Reduced levels of UV-induced unscheduled DNA synthesis in epidermal keratinocytes of patients with xeroderma pigmentosum and correlation with development of skin neoplasms. Cancer Res 49:1927-1930.
15. Li Y, Marion MJ, Rundle A, Brandt-Rauf P. 2003. A common polymorphism in XRCC1 as a biomarker of susceptibility for chemically induced genetic damage. Biomarkers 8:408-414.
16. Marin M, Jost C, Brooks L, Irwin M, O'Nions J. 2000. A common polymorphism acts as an intragenic modifier of p53 behaviour. Nature Genet 25:47-54.
17. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P. 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
18. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
19. Papadakis E, Soulitzis N, Spandidos D. 2002. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumors arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013-1018.
20. Roschke AV, Tonon G, Gelhaus KS, McTyre N, Bussey KJ, Weinstein JN, Kirsch IR. 2003. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63:8634-8647.
21. Rossi G, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, Versari D, Sudano I, Pessina AC, Salvetti A. 2003. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Col Cardiol 41:938-945.
22. Rybicki B, Conti D, Moreira A, Cicek M, Casey G, Witte JS. 2004. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epid Biom Prev 13:23-29.
23. Song J, Yoon Y, Park K, Park J, Hong Y, Hong SH, Kim JO. 2003. Genotype-specific influence on nitric oxide synthetase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells. Clin Chem 49:847-852.
24. Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, Hsu Y, Schnabel F, Estabrook A, Perera FP. 2002. Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat 75:159-166.
25. Vogelstein B, Kinzler K. 1992. p53 function and dysfunction. Cell 70:523-526.
26. Wang Y, Spitz M, Zhou Y, Dong Q, Shete S, Wu X. 2003. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair 2:901-908.
27. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubenstein LV. 1997. An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349.
28. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA. 2002. DNA repair protein levels vis-à-vis anticancer durg resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anti-Cancer Drugs 13:511-519.